Pyxis Oncology Inc (NASDAQ: PYXS) has appointed Thomas Civik as Chief Executive Officer and Chairman of the Board, effective September 4, 2026. The leadership change coincides with the company’s push to advance clinical milestones for its lead candidate, MICVO.

Civik, who served as Interim Chief Executive Officer since February 2026 and joined the board in 2021, brings extensive experience from previous roles at ImCheck Therapeutics, Repare Therapeutics, Five Prime Therapeutics, Foundation Medicine, and Genentech.

Leadership Transition

John Flavin, co-founder and founding Chairman, will transition to the role of Lead Independent Director. Flavin will continue to serve on the board, providing oversight during this strategic phase. The board cited Civik’s demonstrated leadership and disciplined execution during his interim tenure as key factors in the appointment.

Civik expressed gratitude for Flavin’s vision and guidance since the company’s inception. He emphasized the team’s focus on generating clinical evidence for MICVO to address unmet needs in head and neck cancer treatment.

Clinical Pipeline Updates

Pyxis Oncology expects to report updated data from two key studies in 2026:

• Phase 1 monotherapy study of MICVO in second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the fall of 2026. This update will include analysis of patients treated at or below dose cap, covering safety, tolerability, efficacy, and initial durability.
• Phase 1/2 combination study of MICVO with pembrolizumab in first-line R/M HNSCC in the fourth quarter of 2026.

MICVO holds Fast Track Designation from the U.S. Food and Drug Administration for treating adult patients with R/M HNSCC whose disease progressed following platinum-based chemotherapy and anti-PD-(L)1 therapy.

What the Numbers Show

The appointment of a permanent CEO after seven months of interim leadership signals a stabilization of executive management ahead of critical clinical readouts. Civik’s background in commercializing oncology therapies, including roles at companies acquired by major pharmaceutical firms like Amgen and Ipsen, aligns with Pyxis Oncology’s need to navigate complex regulatory and clinical pathways for its antibody-drug conjugate candidate.

Pyxis and Singapore River Cruise (SRC) launched Pyxis L on Sept. 4, 2026, reimagining the traditional bumboat as a venue for private dining and events along the Singapore River.

The vessel pairs a fully air-conditioned interior with rooftop solar panels that reduce reliance on shore power.

A river bumboat built for hosting

Pyxis L features a bespoke hospitality space designed for private dining, events, and curated river journeys. The interior accommodates 24 guests indoors and 12 outdoors.

The vessel can travel for up to 8.5 hours between charges, sufficient for evening dining or scenic loops past the river’s shophouses and bridges.

Solar power that works while you cruise

Ten solar panels built into the roof generate close to 5.8 kW of power during the day. This reduces the frequency and volume of shore power draws. Surplus energy generated by the panels can be exported back to the grid.

When requiring a full charge, Pyxis L uses 10 kW shore charging, taking about six to seven hours. Charging is faster when solar charging runs alongside it. Operators monitor the vessel via Electra, Pyxis’s digital platform for remote monitoring.

Built in Singapore, for the Singapore River

Built in Singapore, Pyxis L is the newest addition to Pyxis’s electric vessel line-up. It utilizes the same catamaran hull form, core electric propulsion, battery, and digital systems platform, adapted for a purpose-built hospitality experience.

Part of a longer track record

Pyxis L follows several milestones for the Singapore-based maritime electrification start-up, which launched in 2022:

• March 2024: Unveiled X Tron, Singapore’s first fully electric port passenger launch.
• Late 2024: Opened the first public marine electric charging point at Marina South Pier with SP Group.
• 2025: Introduced Pyxis R, Singapore’s first solar-powered river boat.

"With Pyxis L, we wanted to go beyond the electric platform itself," said Tommy Phun, Founder of Pyxis. "What really sets Pyxis L apart is the interior. We designed it as a space for hosting, where the experience on board matters as much as the journey itself."

Commercial traction

SRC has confirmed an order for a second Pyxis L from Pyxis, expanding the new river cruise offering within its fleet.

"Pyxis L allows us to retain the character of the Singapore River journey while elevating the onboard experience," said Ms Tieu Xin Yue of Singapore River Cruise. "It gives us a vessel that’s truly built for hospitality."

What the Numbers Show

The confirmed order for a second Pyxis L indicates immediate commercial validation of the platform. By adapting an existing electric propulsion and battery architecture into a hospitality-specific vessel, Pyxis demonstrates asset reuse efficiency, leveraging prior R&D investments in the X Tron and Pyxis R platforms to enter the high-margin private events segment without developing a new hull from scratch.